Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610524 | 1.00 | FKBP1A (1.00) | FKBP1A | |
| SCHEMBL10066851 | 0.96 | FKBP1A (0.92) | FKBP1A | |
| SCHEMBL26936134 | 0.89 | FKBP1A (0.80) | FKBP1A | |
| SCHEMBL5965893 | 0.89 | FKBP1A (0.80) | FKBP1A | |
| SCHEMBL1776165 | 0.88 | FKBP1A (1.00) | FKBP1A | |
| SCHEMBL4679960 | 0.88 | FKBP1A (1.00) | FKBP1A | |
| SCHEMBL5966310 | 0.87 | FKBP1A (0.77) | FKBP1A | |
| SCHEMBL8180938 | 0.87 | FKBP1A (0.77) | FKBP1A | |
| SCHEMBL7399179 | 0.86 | FKBP1A (0.76) | FKBP1A | |
| SCHEMBL26210430 | 0.86 | FKBP1A (0.78) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227859-B1 | NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS | ALCON INC (CH) | 2006-08-09 | — | — | EP | claimed |
| US-6376517-B1 | FOR TREATING VISION LOSS, PREVENTING VISION DEGENERATION, AND PROMOTING VISION REGENERATION (?NEOPSIS?) | GPI NIL HOLDINGS, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0777478-B1 | INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010036947-A1 | Pipecolic acid derivative hair growth compositions and uses | GPI NIL HOLDINGS, INC. (US) | 2001-11-01 | — | — | US | claimed |
| US-6187784-B1 | ALOPECIA TREATMENT; FKBP-IMMUNOPHILIN AFFINITY | GPI NIL HOLDINGS, INC. | 2001-02-13 | — | — | US | claimed |
| US-5843960-A | Inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 1998-12-01 | — | — | US | claimed |
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1109554-A2 | PIPECOLIC ACID DERIVATIVES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000009109-A2 | PIPECOLIC ACID DERIVATIVES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036947-A1 | Pipecolic acid derivative hair growth compositions and uses | PIP5K1C, PIP4K2C, PIP5K1A | FKBP1A 510/4885 |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | FKBP1A 2/4885 |
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | FKBP1A 4606/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | FKBP1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.